Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness
Overview
- Phase
- Phase 4
- Intervention
- bevacizumab
- Conditions
- Diabetic Retinopathy
- Sponsor
- Kyungpook National University Hospital
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Central macular thickness
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
This study is to investigate the effect of adjunctive intravitreal bevacizumab (IVB) before panretinal photocoagulation (PRP) compared with only PRP on central macular thickness and retinal nerve fiber layer thickness in patients with severe diabetic retinopathy without macular edema.
Detailed Description
This prospective randomized study included 30 patients (60 eyes) with severe nonproliferative diabetic retinopathy or non-high-risk proliferative diabetic retinopathy. They had weekly PRP treatments in 3 sessions and they were randomly assigned to IVB group who had adjunctive IVB within 1 week before first PRP and control group who had only PRP. CMT, RNFL, and best-corrected visual acuity (BCVA) were measured
Investigators
Dong Ho Park
Clinical professor
Kyungpook National University Hospital
Eligibility Criteria
Inclusion Criteria
- •patients with severe NPDR or early PDR without macular edema
- •best-corrected visual acuity (BCVA) of 20/25 or better
- •patients who were followed up for at least 6 months after the first PRP.
Exclusion Criteria
- •patients with retinal or choroidal diseases except diabetic retinopathy
- •contraindications to fluorescein angiography (FA) or bevacizumab
- •patients who had previous treatments including anti-angiogenic medications and laser photocoagulation
- •patients with previous vitrectomy
- •patients with uncontrolled hypertension, a recent myocardial infarction or cerebral vascular accidents.
Arms & Interventions
IVB group
Patients were treated with IVB injections approximately within 1 week before the first PRP. Then patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
Intervention: bevacizumab
Outcomes
Primary Outcomes
Central macular thickness
Time Frame: 6 months after first PRP session
central macular thickness measured by Cirrus HD optical coherence tomography
Secondary Outcomes
- Retinal nerve fiber layer thickness(6 months after first PRP session)